Baird Capital has completed fundraising for its fourth Venture Capital fund (BVP IV). The fund was significantly oversubscribed and closed at $185 million, exceeding its initial target of $150 million and the size of its previous fund. The fund was anchored by support from numerous institutions, foundations and family offices.
Baird Capital’s Venture team is led by partners Gordon Pan, Michael Liang, Jim Pavlik, Benedict Rocchio and Principal Nicole Walker, as well as Venture Partners David Gregorka, Don Layden and Fred Robertson.To date, BVP IV has already invested in five companies, including:
- Integrated Diagnostics
- NeuMoDx Molecular
Baird Capital’s Venture Capital team partners with entrepreneurs to build innovative, high-growth companies within the Technology-Enabled Services and Healthcare sectors. Committing $10 million to $15 million in equity over the life of an investment, the Venture Capital team looks to partner with companies with strong and experienced management teams, capital efficient business models, and differentiated products or services that address large market opportunities. To view Baird Capital’s current and historical investments, click here.